XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer

被引：27
|
作者：
Feng, Jifeng [2 ,3 ]
Sun, Xinchen [1 ]
Sun, Ning [1 ]
Qin, Shukui [4 ]
Li, Fan [1 ]
Cheng, Hongyan [1 ]
Chen, Baoan [1 ]
Cao, YuanDong [1 ]
Ma, Jun [1 ]
Cheng, Lu [5 ]
Lu, Zuhong [5 ]
Ji, Jiazhong [6 ]
Zhou, Yingfeng [6 ]
机构：
[1] Southeast Univ, Zhongda Hosp, Nanjing 210009, Peoples R China
[2] Southeast Univ, Sch Med, Nanjing 210009, Peoples R China
[3] Jiangsu Canc Hosp, Nanjing 210009, Peoples R China
[4] PLA, Hosp 81, Dept Oncol, Nanjing 210034, Peoples R China
[5] Southeast Univ, Lab Mol & Biomol Elect, Nanjing 210096, Peoples R China
[6] Jiangbei People Hosp, Dept Oncol, Nanjing 210048, Peoples R China
来源：
ACTA BIOCHIMICA ET BIOPHYSICA SINICA | 2009年 / 41卷 / 05期
关键词：
single nucleotide polymorphism; gene-chip; XPA; XPG; nucleotide excision repair; non-small cell lung cancer; chemotherapy; NUCLEOTIDE-EXCISION-REPAIR; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; DNA-REPAIR; GROUP-A; TRANSCRIPTION; RISK; BINDING; ERCC1; RNA;
D O I：
10.1093/abbs/gmp027
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A -> G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.
引用
收藏
页码：429 / 435
页数：7
相关论文
共 50 条
  • [1] Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy
    Shi, Hong-Bing
    Li, Xiao-Dong
    Jiang, Jing-Ting
    Zhao, Wei-Qing
    Ji, Mei
    Wu, Chang-Ping
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (03) : 681 - 685
  • [2] Bevacizumab Plus Platinum-Based Chemotherapy In Advanced Non-Small Cell Lung Cancer
    Wagstaff, Antona J.
    Keam, Susan J.
    McCormack, Paul L.
    [J]. BIODRUGS, 2009, 23 (03) : 187 - 196
  • [3] Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
    Furqan, Muhammad
    Abu-Hejleh, Taher
    Stephens, Laura M.
    Hartwig, Stacey M.
    Mott, Sarah L.
    Pulliam, Casey F.
    Petronek, Michael
    Henrich, John B.
    Fath, Melissa A.
    Houtman, Jon C.
    Varga, Steven M.
    Bodeker, Kellie L.
    Bossler, Aaron D.
    Bellizzi, Andrew M.
    Zhang, Jun
    Monga, Varun
    Mani, Hariharasudan
    Ivanovic, Marina
    Smith, Brian J.
    Byrne, Margaret M.
    Zeitler, William
    Wagner, Brett A.
    Buettner, Garry R.
    Cullen, Joseph J.
    Buatti, John M.
    Spitz, Douglas R.
    Allen, Bryan G.
    [J]. REDOX BIOLOGY, 2022, 53
  • [4] PROGNOSTIC IMPORTANCE OF RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Radosavljevic, D.
    Kezic, I.
    Jelic, S.
    Golubicic, I.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 111 - 111
  • [5] XPA A23G polymorphism and lung cancer risk: a meta-analysis
    Ji-Hong Zou
    Li An
    Shi Chen
    Li-Qun Ren
    [J]. Molecular Biology Reports, 2012, 39 : 1435 - 1440
  • [6] XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy
    Zou, H. Z.
    Zhao, Y. Q.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2015, 14 (01) : 500 - 506
  • [7] Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer
    Zhang, Tao
    Zhang, Dong-ming
    Zhao, Da
    Hou, Xiao-ming
    Yang, Tian-ning
    [J]. JOURNAL OF BUON, 2014, 19 (03): : 742 - 748
  • [8] A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer
    Ballas, MS
    Dennis, PA
    [J]. CANCER BIOLOGY & THERAPY, 2005, 4 (12) : 1316 - 1317
  • [9] Is the platinum-based chemotherapy necessary for elderly patients with advanced non-small cell lung cancer (NSCLC)?
    Daga, H.
    Takeda, K.
    Kiyota, H.
    Tokunaga, S.
    Nanjo, S.
    Sumitani, M.
    Shoji, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] XPA A23G polymorphism and lung cancer risk: a meta-analysis
    Zou, Ji-Hong
    An, Li
    Chen, Shi
    Ren, Li-Qun
    [J]. MOLECULAR BIOLOGY REPORTS, 2012, 39 (02) : 1435 - 1440
12345